fig2

Figure 2. Establishment and evaluation of a CDK4/6-based nomogram in PDAC cohorts. (A) Nomogram parameters, including gender, age, tumor size, diabetes, CA199 level, lymphatic metastasis, tumor differentiation, perineural invasion, tumor embolus, distant metastasis, TNM stage, and CDK4/6 expression, were used to predict 1-, 2- and 3-year survival in PDAC patients; (B and C) Time-dependent ROC curves comparing the nomogram, clinical parameters, and TNM stage in the training and validation cohorts. CDK4/6: Cyclin-dependent kinases 4 and 6; PDAC: pancreatic ductal adenocarcinoma; TNM: tumor size, node, and metastasis; ROC: receiver operating characteristic.